Closing the Comorbidity Gap for People Living with HIV
A Randomized Controlled Trial of Fostemsavir to Reduce Inflammaging
Madeleine Durand
University of Montreal
Background
HIV is a chronic manageable disease, but it remains incurable. As a result, aging well with HIV is a public health priority.
The study population of this research project are people living with HIV with undetectable viral load, and the overarching goal of this program is to close the prognostic gap for these people, so that they may have an optimal health related quality of life.
What is the main aim of the study?
At present, no intervention has been shown effective to reduce the risk of cardiovascular disease that is secondary to the chronic inflammation present in people living with HIV.
It will establish whether treatment with fostemsavir can reduce inflammation and comorbidities such as cardiovascular disease in this population.
